269 related articles for article (PubMed ID: 37975977)
21. Systemic treatment in patients with malignant pleural mesothelioma - real life experience.
Ziółkowska B; Cybulska-Stopa B; Papantoniou D; Suwiński R
BMC Cancer; 2022 Apr; 22(1):432. PubMed ID: 35443624
[TBL] [Abstract][Full Text] [Related]
22. Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos-Exposed Subjects.
Guarrera S; Viberti C; Cugliari G; Allione A; Casalone E; Betti M; Ferrante D; Aspesi A; Casadio C; Grosso F; Libener R; Piccolini E; Mirabelli D; Dianzani I; Magnani C; Matullo G
J Thorac Oncol; 2019 Mar; 14(3):527-539. PubMed ID: 30408567
[TBL] [Abstract][Full Text] [Related]
23. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
Scherpereel A; Mazieres J; Greillier L; Lantuejoul S; Dô P; Bylicki O; Monnet I; Corre R; Audigier-Valette C; Locatelli-Sanchez M; Molinier O; Guisier F; Urban T; Ligeza-Poisson C; Planchard D; Amour E; Morin F; Moro-Sibilot D; Zalcman G;
Lancet Oncol; 2019 Feb; 20(2):239-253. PubMed ID: 30660609
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial.
Stahel RA; Riesterer O; Xyrafas A; Opitz I; Beyeler M; Ochsenbein A; Früh M; Cathomas R; Nackaerts K; Peters S; Mamot C; Zippelius A; Mordasini C; Caspar CB; Eckhardt K; Schmid RA; Aebersold DM; Gautschi O; Nagel W; Töpfer M; Krayenbuehl J; Ribi K; Ciernik IF; Weder W
Lancet Oncol; 2015 Dec; 16(16):1651-8. PubMed ID: 26538423
[TBL] [Abstract][Full Text] [Related]
25. Malignant Pleural Mesothelioma: State of the art and advanced cell therapy.
Facchetti G; Petrella F; Spaggiari L; Rimoldi I
Eur J Med Chem; 2017 Dec; 142():266-270. PubMed ID: 28800871
[TBL] [Abstract][Full Text] [Related]
26. [Malignant pleural mesothelioma: diagnosis and treatment].
Delourme J; Dhalluin X; Cortot AB; Lafitte JJ; Scherpereel A
Rev Pneumol Clin; 2013 Feb; 69(1):26-35. PubMed ID: 23333048
[TBL] [Abstract][Full Text] [Related]
27. BAP1 Loss by Immunohistochemistry Predicts Improved Survival to First-Line Platinum and Pemetrexed Chemotherapy for Patients With Pleural Mesothelioma: A Validation Study.
Louw A; Panou V; Szejniuk WM; Meristoudis C; Chai SM; van Vliet C; Lee YCG; Dick IM; Firth T; Lynggaard LA; Asghari AB; Vyberg M; Hansen J; Creaney J; Røe OD
J Thorac Oncol; 2022 Jul; 17(7):921-930. PubMed ID: 35489694
[TBL] [Abstract][Full Text] [Related]
28. A Phase II Trial of Nivolumab With Chemotherapy Followed by Maintenance Nivolumab in Patients With Pleural Mesothelioma After Surgery: The NICITA Study Protocol.
Shah R; Klotz LV; Chung I; Feißt M; Schneider MA; Riedel J; Bischoff H; Eichhorn ME; Thomas M
Clin Lung Cancer; 2021 Mar; 22(2):142-146. PubMed ID: 33158765
[TBL] [Abstract][Full Text] [Related]
29. Phase II Trial of Cediranib in Combination With Cisplatin and Pemetrexed in Chemotherapy-Naïve Patients With Unresectable Malignant Pleural Mesothelioma (SWOG S0905).
Tsao AS; Miao J; Wistuba II; Vogelzang NJ; Heymach JV; Fossella FV; Lu C; Velasco MR; Box-Noriega B; Hueftle JG; Gadgeel S; Redman MW; Gandara DR; Kelly K
J Clin Oncol; 2019 Oct; 37(28):2537-2547. PubMed ID: 31386610
[TBL] [Abstract][Full Text] [Related]
30. Schedule-Dependent Treatment Increases Chemotherapy Efficacy in Malignant Pleural Mesothelioma.
Karatkevich D; Deng H; Gao Y; Flint E; Peng RW; Schmid RA; Dorn P; Marti TM
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233258
[TBL] [Abstract][Full Text] [Related]
31. [Anti-tumor immunotherapy in malignant pleural mesothelioma].
Scherpereel A; Willemin MC; Wasielewski E; Dhalluin X
Rev Mal Respir; 2018 Apr; 35(4):465-476. PubMed ID: 29415822
[TBL] [Abstract][Full Text] [Related]
32. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
[TBL] [Abstract][Full Text] [Related]
33. New Concepts in the Treatment of Malignant Pleural Mesothelioma.
Wald O; Sugarbaker DJ
Annu Rev Med; 2018 Jan; 69():365-377. PubMed ID: 29029582
[TBL] [Abstract][Full Text] [Related]
34. Management of Advanced Pleural Mesothelioma-At the Crossroads.
Nowak AK; Jackson A; Sidhu C
JCO Oncol Pract; 2022 Feb; 18(2):116-124. PubMed ID: 34491782
[TBL] [Abstract][Full Text] [Related]
35. Optimal Therapy of Advanced Stage Mesothelioma.
Disselhorst MMJ; Burgers SJA; Baas P
Curr Treat Options Oncol; 2017 Aug; 18(8):48. PubMed ID: 28681207
[TBL] [Abstract][Full Text] [Related]
36. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial.
Ceresoli GL; Aerts JG; Dziadziuszko R; Ramlau R; Cedres S; van Meerbeeck JP; Mencoboni M; Planchard D; Chella A; Crinò L; Krzakowski M; Rüssel J; Maconi A; Gianoncelli L; Grosso F
Lancet Oncol; 2019 Dec; 20(12):1702-1709. PubMed ID: 31628016
[TBL] [Abstract][Full Text] [Related]
37. Pemetrexed-loaded nanoparticles targeted to malignant pleural mesothelioma cells: an in vitro study.
Cova E; Pandolfi L; Colombo M; Frangipane V; Inghilleri S; Morosini M; Mrakic-Sposta S; Moretti S; Monti M; Pignochino Y; Benvenuti S; Prosperi D; Stella G; Morbini P; Meloni F
Int J Nanomedicine; 2019; 14():773-785. PubMed ID: 30774332
[TBL] [Abstract][Full Text] [Related]
38. How I treat malignant pleural mesothelioma.
Viscardi G; Di Liello R; Morgillo F
ESMO Open; 2020 Mar; 4(Suppl 2):e000669. PubMed ID: 32156681
[TBL] [Abstract][Full Text] [Related]
39. Management options for malignant pleural mesothelioma: clinical and cost considerations.
Goudar RK
Drugs; 2007; 67(8):1149-65. PubMed ID: 17521217
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Real-World Toxicity and Survival of Combination Immunotherapy in Pleural Mesothelioma-RIOMeso.
McNamee N; Harvey C; Gray L; Khoo T; Lingam L; Zhang B; Nindra U; Yip PY; Pal A; Clay T; Arulananda S; Itchins M; Pavlakis N; Kao S; Bowyer S; Chin V; Warburton L; Pires da Silva I; John T; Solomon B; Alexander M; Nagrial A
J Thorac Oncol; 2024 Apr; 19(4):636-642. PubMed ID: 38036250
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]